Adocia has announced that the USPTO (United States Patent and Trademark Office) and the EPO (European Patent Office) have issued a patent covering BioChaperone PDGF (Platelet Derived Growth Factor) formulations for chronic wound treatment, including diabetic foot ulcer, to Adocia.
This patent covers the innovative formulation of PDGF with a polymer of the platform BioChaperone®, property of Adocia. This polymer has been designed by Adocia to form a molecular complex with this specific growth factor.
Thanks to this technology, PDGF is protected from enzymatic degradation enabling a reduction of the PDGF dose by a factor of three and also the frequency of administration, from once-a-day to once-every-two days.
These significant therapeutic advantages have been confirmed by the positive results of the phase II clinical trial in India, published in a press release on April 23, 2012. Phase III clinical trials are in preparation and the first study could be initiated before year-end in India.
“The issuance of these patents by American and European agencies validates the BioChaperone technology in terms of novelty and innovation,” said Olivier Soula, VP, R&D director and cofounder of Adocia.
“We have the confirmation of the intellectual protection of our product for the treatment of chronic wounds for the next fifteen years,” said Gérard Soula, president CEO and cofounder of Adocia. “This is a key element for licensing our product to pharmaceutical companies.”